Hook
On a quiet Tuesday in late 2025, Baichuan Intelligent, once hailed as China’s fourth-most-promising large language model startup, confirmed what many insiders had whispered for months: it was abandoning the general-purpose LLM race to dive headfirst into medical AI. The news came not with a press release, but with a slow bleed of departures—co-founders, including the well-respected Ru Liyun, had already left, citing irreconcilable differences over technical direction. The loudest voice in the room, founder Wang Xiaochuan, had won. But in the echo of that victory, a deeper question emerged: in an industry already plagued by data silos, regulatory bottlenecks, and trust deficits, can a centralized medical AI built by one man’s vision truly serve humanity? Or does the path to health sovereignty require something more—something forged in code, law, and the quiet consensus of a distributed network?
Context
Baichuan’s story is not unique. It is the archetypal tale of a 2023-era LLM unicorn that raised $700 million at a $2.8 billion valuation, only to see the air thin as the market demanded sustainable revenue over raw parameter counts. The company’s initial pitch was a general-purpose foundation model, Baichuan series, which briefly entered top-10 rankings for Chinese LLMs. But by 2024, open-source alternatives like Qwen, DeepSeek, and Yi had surpassed it in key benchmarks such as code generation and mathematical reasoning. Meanwhile, competitors like Zhipu AI and Moonshot AI continued to burn capital on scaling laws, each upgrade costing tens of millions in GPU compute.
Recognizing the trap, Wang made a radical bet: pivot entirely to medical AI—a vertical with high data moats, long sales cycles, and a regulatory labyrinth. The company would launch a medical LLM called M4 and a family doctor agent named Baixiao Yi. It would shed its enterprise API business, slash general-purpose research, and rely on the $700 million war chest to survive the long winter of hospital procurement. But the move came at a cost: the departure of the entire founding team, the loss of technical talent, and a strategic isolation that left Baichuan a solitary player in a crowded arena.
Core
To understand Baichuan’s gamble through a blockchain lens, we must first examine the three core tensions it exposes in the current AI landscape.
1. The Centralization of Trust Baichuan’s model is a walled garden. All patient data, diagnostic suggestions, and model updates flow through a single entity. Even if Wang’s intentions are pure, the architecture invites single points of failure: a compromised server, a biased training dataset, a sudden change in regulatory interpretation. Code is law, but conscience is the interpreter—and when the interpreter is a centralized boardroom, the law can shift without warning. In decentralized health AI, trust is distributed across nodes, each validating the integrity of the data and the model. Projects like Bittensor and Sahara AI are experimenting with incentive structures where medical institutions contribute encrypted data to a collective model, earning tokens for verifiable improvements. The model’s weights are transparent, audit trails immutable. Baichuan, by contrast, asks hospitals and patients to trust a black box.
2. The Fragmentation of Liquidity This mirrors a pattern I’ve observed across Layer2 scaling: dozens of chains promising the same solution, yet the same small user base spreads thinner. In medical AI, we see a similar fragmentation—every hospital system, every province, every country deploying its own AI model, each with its own compliance framework. Baichuan’s M4 may excel in one hospital’s radiology department but fail in another’s because of different imaging equipment or demographics. The true scaling challenge is not compute, but interoperability. A decentralized health AI network could standardize model interfaces through on-chain registries. A doctor in Shanghai could query a model trained on data from Beijing and Bangalore, with differential privacy guaranteeing that no patient record leaves its jurisdiction. The liquidity of knowledge—not capital—is what compounds.
3. The Regulatory Tightrope Baichuan’s M4 will likely avoid NMPA Class II/III certification by positioning itself as a “clinical decision support tool” rather than a diagnostic device. This is a familiar dance in medical AI: call it a co-pilot, not a pilot. But the risk remains. A hallucination about a drug dose, a missed anomaly in a CT scan, and the liability falls squarely on the company. On-chain governance offers a different path: smart contracts that encode liability, insurance pools funded by staked tokens, and DAO-based verification of model performance across real-world settings. The loudest voice is rarely the most aligned. In a decentralized system, alignment emerges from on-chain voting and economic penalties, not from a single founder’s gut.
Contrarian
The contrarian view, of course, is that decentralization in medical AI is naive. Hospitals require reliable, auditable systems today, not a utopian vision of tokenized health records. Baichuan’s $700 million gives it the capacity to hire top regulatory lawyers, run multi-site clinical trials, and win the slow game of procurement. It can sign exclusive data-sharing agreements with major hospitals, creating a data flywheel that no decentralized competitor can match. Wang’s previous attempt at medical AI—the startup Guangnian Zhiwai, acquired by Meituan—might give him unique insights into what not to do. Solitude is the only auditor that never sleeps, but it also means no one to share the burden.
Furthermore, on-chain models suffer from latency and cost. A doctor cannot wait for a Ethereum transaction to confirm before diagnosing a stroke. Verifiable computation, such as zk-SNARKs, adds overhead that makes real-time inference impractical. Centralized servers on AWS are, for now, the only way to achieve sub-100ms response times. Baichuan’s pivot may be the most pragmatic path available: focus on a vertical where capital, not speed, is the competitive moat.
Takeaway
Baichuan’s story is a parable for the entire AI industry. The pivot to medical AI is not a retreat, but a deepening—a recognition that the most valuable applications of intelligence are not those that answer every question, but those that ask the right ones about our most fragile asset: our health. Yet the architecture of trust remains the fundamental question. Will we build healthcare systems that are opaque, fragile, and dependent on a single founder’s vision? Or will we design networks where trust is distributed, data is sovereign, and alignment is encoded, not asserted? The answer will not come from a press release. It will emerge from the quiet, deliberate work of auditors, developers, and communities who refuse to confuse speed with progress, or scale with value. The silence between the lines of Baichuan’s announcement is not emptiness. It is the sound of an industry searching for a more resilient foundation.
Solitude is the only auditor that never sleeps. But perhaps the real audit has only just begun.
